Cyclosporin A Therapy of Immune-Mediated Thrombocytopenia in Children
To the Editor. lmmune thrombocytopenic purpura (ITP) of childhood is usually a self-limited disorder with spontaneous and complete recovery in 80% to 90% of cases. In the remaining cases, the course is chronic. Splenectomy resolves thrombocytopenia in 70% to 75% of chronic cases, but in a small group of cases (5% of all cases), the thrombocytopenia becomes refractory to therapeutic intervention including steroid therapy, intravenous Ig, RhJD) immune globulin and immunosuppressive chemotherapeutic agents.' Thus, new therapeutic modalities are needed for these refractory ITP cases.
1TP appears to be secondary to platelet reactive antibodies produced by B cells.' More recently, platelet reactive T cells have been identified' and probably supply "help" to platelet-reactive B cells. Cyclosporin A (CsA) has the ability to inhibit T-cell and T-celldependent B-cell function. In addition, it has been reported to be successful in treatment of adults with refractory chronic ITP.4~7
Moreover, because it has been suggested that I T P is primarily caused by a T-cell defect rather than a B-cell defect, specific suppression of T-cell suppression may be efficacious.x The efficacy of CsA in children with chronic I T P has not been studied. We evaluated the ability of CsA to increase platelet counts in children with refractory ITP in a prospective pilot study.
Children 5 I5 years of age were eligible if they had I T P dependent on immunosuppressive therapy 2 3 months. Eligibility requirements included mandatory bone marrow evaluation, normal liver or renal function and no evidence of HIV, or systemic lupus erythematosis (positive antinuclear antibody). No treatment excluding prednisone could have been given more than 4 weeks from entry on study. CsA was statted at a dose of 5 mgikgld divided into two doses and increased to 10 mg/kg/d if there was no response after 2 weeks. Therapy was stopped after 4 weeks if there was no response. CsA (Sandimmun; Sandoz Pharmaceuticals, Dorval, Quebec, Canada) was supplied without cost to the patients treated in Canada. Platelet counts, CsA levels (using whole blood monoclonal assay; Abbott Laboratories, Chicago, IL), renal and liver functions, and evaluation for clinical toxicity were. monitored at least weekly.
We enrolled five children with chronic ITP. Ages ranged from 3 to 14 years with a median of 11 years. Ratio of male to female was 4:1 ( Table 1 ). All children had been previously treated with prednisone and four of five had also proven refractory to intravenous
immune globulin (WinRho; Rh Pharmaceuticals, Winnipeg, Canada) was tried in two children with no response before entry on study. One child had concurrent warm antibody autoimmune hemolytic anemia. All patients had a starting platelet count s40 X Evaluation for response to CsA therapy showed that one patient had an increase in platelet count 2 2 5 cell X IO9 celldL at 5 mg/ kg/d and three additional patients at 10 mg/kg/d (Fig 1, A and B) . Only two had an increase in platelet count of 250 X IO9 ce1ldL and none had an increase of 2 1 0 0 X IO9 cellsL (Fig IB) . Whole blood cyclosporine levels 2 150 @L were attained in all patients. Length of any response (platelets 2 2 5 X IO9 cells/L) was 1 week in two patients, 2 weeks in one, and 4 weeks in one. All responses were transient with the longest response lasting 4 weeks. Platelet counts declined in four children while on CsA.
Toxicity observed in children while on cyclosporine was headache: gastrointestinal upset/decreased appetite,' irritability,' chest pain,' peripheral neuritis,' and hypertension.' Although all patients were on prednisone before entering study, all of these symptoms began after starring CsA. None of the patients had evidence of renal dysfunction (creatinine 2 2 X baseline) and/or liver dysfunction (ALT or AST 2 150).
Despite the wide variation in CsA levels during therapy and small numbers of children studied, the data suggested a relationship between the CsA levels and increase in platelets counts (Fig 2; R =  .72 ). On the other hand, relatively high levels of CsA (>S00 p g L ) were required to obtain increases of 250 X 109L over baseline.
In summary, we prospectively evaluated the efficacy of T-celldirected therapy using CsA in children with chronic ITP. Although a small number of children were evaluated. we saw a consistent For personal use only. on November 11, 2017. by guest www.bloodjournal.org From response pattern in four of five children. However, the response was minimal and transient. Although not life threatening, toxicity associated with CsA treatment appeared to be greater than that seen in other children receiving CsA for other indications with similar blood levels. The trend toward a direct correlation of whole blood CsA levels and platelet responsiveness implies that relatively high blood levels of CsA ( 2 5 0 0 p g L ) are necessary to attain a platelet increase of 250 X IO9&. Attainment of high CsA levels in these children appeared to result in intolerable toxicity for some. These results suggest that CsA, as given in this trial, is not an effective
